Depomed, a specialty pharmaceutical company that commercializes products for pain and neurology related disorders, announced that on July 17, 2014, Judge Joel A. Pisano of the US District Court for the District of New Jersey entered an order preliminarily enjoining Actavis Elizabeth LLC and Actavis Inc. from marketing a generic version of Gralise (gabapentin) prior to the Court's issuance of an opinion in the matter. The order indicates the Court expects to issue an opinion in short order.
The patents asserted in the lawsuits expire between September 2016 and February 2024 and include US Patent Nos. 6,635,280; 6,488,962; 7,438,927; 7,731,989; 8,192,756; 8,252,332; and 8,333,992.
On May 20, 2014, a bench trial was completed before Judge Pisano in the patent litigation between Depomed and defendants Actavis Elizabeth LLC and Actavis Inc. related to an Abbreviated New Drug Application filed by Actavis seeking to market generic versions of 300mg and 600mg dosage strengths of Gralise prior to the expiration of the patents asserted in the litigation.